newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities